Scholars Central

EditorialPublished 2013

Recent Developments in EU and US Pharmacovigilance Legislation

Authors: Gianluca Montanari-Vergallo

Journal of Pharmacovigilance

Volume 1 · Issue 2 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The evolution of EU and US pharmacovigilance legislation highlights two trends. The first is to strengthen the instruments of protection of human health through, inter alia, the continuous monitoring of the risk-benefit ratio of drugs, greater transparency and the power to penalize producers for the failure to meet the pharmacovigilance obligations. The second trend manifests the partial harmonization of the different pharmacovigilance systems. However, this goal is still far away. In order to achieve it would be necessary to establish an identical definition of adverse drug reaction in both the EU and US legislation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmacovigilance.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacovigilance
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Gianluca Montanari-Vergallo”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels